New CT scanner could spot hidden liver cancer after treatment
NCT ID NCT07351669
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a special type of CT scan (spectral CT) can better detect remaining liver cancer after a standard treatment called TACE. About 121 adults with liver cancer who have had TACE will get a spectral CT scan, and results will be compared to standard CT and to actual tissue samples. The goal is to see if spectral CT is more accurate at telling whether the treatment fully worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- spectral CT (imaging technique)
- What this could lead to
- If successful, spectral CT could become a more accurate way to see if liver cancer treatment worked, helping doctors decide next steps sooner.
- What could go wrong
- This is a small, early-stage diagnostic study, not a treatment trial. The new CT method may not prove more accurate than standard CT in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongda Hospital Southeast University
RECRUITINGNanjing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink liver tumors?
- Ancient herbal mix could boost liver health in advanced cancer
- CT scans could make heart artery procedures faster and safer
- Double immune attack: new drug combo takes on advanced liver cancer
- Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working
- Radiation and drug combo shows promise for tough liver cancers